• BRD4–RAC1 Co-Targeting in Breast Cancer

  2026-08-22

  The 2021 International Journal of Biological Sciences study shows that simultaneous inhibition of BRD4 and RAC1 suppresses growth, stemness, migration, and tumorigenesis across breast cancer subtypes. Its mechanistic contribution is the identification of a c-MYC–G9a–FTH1 axis and HDAC1-associated chromatin remodeling as central points of convergence for the combination.

• T7 RNA Polymerase for HEY2 RNA Workflows

  2026-08-21

  Build defined RNA inputs for HEY2 gain-of-function, rescue, antisense, and hybridization assays with a promoter-specific in vitro transcription workflow. This guide connects the reference study’s cardiac metabolism findings to practical template design, reaction setup, purification, and troubleshooting using a recombinant enzyme expressed in E. coli.

• Ginsenosides and High-Altitude Hypoxia Injury

  2026-08-20

  The 2024 Frontiers in Pharmacology study links ginsenoside-mediated protection of lung and kidney tissues to coordinated regulation of the PHD2/HIF-1α/EPO axis. Using physiological, histological, molecular, and fluorescence-based endpoints, the authors show reduced tissue hypoxia, oxidative stress, inflammation, and blood-flow abnormalities in a simulated high-altitude model.

• Tin Mesoporphyrin IX in HO-1 Assays

  2026-08-20

  Tin Mesoporphyrin IX (chloride) provides a reversible, high-affinity way to separate heme oxygenase activity from HO-1 expression in biochemical, metabolic, and antiviral models. This practical guide connects nanomolar enzyme inhibition with ROS, HBV replication, and heme-catabolism workflows while emphasizing controls, assay compatibility, and interpretation limits.

• Paroxetine Mesylate: Research Workflows

  2026-08-19

  Paroxetine Mesylate combines high-affinity SERT activity with measurable CYP2D6, GRK2, MET, and ERBB3-related pharmacology, making it useful for integrated neuropharmacology and oncology studies. This guide converts that polypharmacology into practical cell-based workflows, assay controls, and troubleshooting decisions.

• LDN-193189: From BMP Mechanism to Translation

  2026-08-19

  LDN-193189 is a selective BMP type I receptor inhibitor that enables researchers to connect ALK2 and ALK3 signaling with Smad activity, epithelial barrier phenotypes, and translational disease models. This thought-leadership guide outlines how to deploy the compound rigorously, interpret cross-domain evidence, and distinguish validated biology from forward-looking hypotheses.

• How Oxidative Stress Activates ATM: Structural Insights

  2026-08-18

  Howes, Perisic, and Williams used cryo-EM and biochemical analysis to define how hydrogen peroxide activates the DNA damage kinase ATM. Their structure links a redox-sensitive disulfide bridge to dimer rotation, release of an autoinhibitory region, kinase-domain remodeling, and productive p53 substrate binding.

• TAI-1 Hec1 Inhibitor: Workflows & Applications

  2026-08-18

  TAI-1 gives cancer researchers a practical route to connect Hec1–Nek2 disruption with mitotic failure, proliferation loss, and apoptotic cell death induction. This guide combines dose-response, chromosome-imaging, combination-treatment, and replication-stress assays with troubleshooting strategies for triple negative breast cancer research and liver cancer research.

• Chenodeoxycholic Acid: From FXR Signal to Assay Design

  2026-08-17

  Chenodeoxycholic Acid (CDCA) is more than an FXR agonist: it can serve as a mechanistic probe linking bile acid metabolism to transcriptional and injury-response assays. This guide translates recent FXR–KLF11 findings into a rigorous framework for experimental design, controls, and interpretation.

• Central Control of Opioid Mechanical Hypersensitivity

  2026-08-17

  Yin et al. identify a brain-to-spinal opioid pathway linking MOR-expressing neurons in the lateral parabrachial nucleus, dynorphin neurons in the hypothalamus, and KOR-expressing GABAergic neurons in the spinal dorsal horn. Their findings distinguish central control of mechanical opioid-induced hypersensitivity and tolerance from better-established thermal mechanisms and provide a circuit framework for receptor- and pathway-level experiments.

• ETS1–SENP2 Axis in Bronchopulmonary Dysplasia

  2026-08-16

  A 2026 study identifies ETS1 as a transcriptional regulator that protects against hyperoxia-associated bronchopulmonary dysplasia by coordinating SENP2-dependent deSUMOylation, HSPA8 binding, and FUNDC1 degradation. The findings connect mitochondrial quality control with alveolar injury and suggest that excessive mitophagy, rather than autophagy activation in general, may be a context-dependent therapeutic target.

• Plant Cell Lysis Buffer for WB and IP: MAPK10 Assays

  2026-08-15

  Build cleaner Western blotting, immunoprecipitation, and co-IP workflows from plant, animal, fungal, or bacterial samples with a non-denaturing extraction system. This guide translates MAPK10–KRT16 pathway findings into practical sample-preparation, assay-selection, and troubleshooting decisions.

• hCG, H3K27 Methylation, and CXCL10 in Decidua

  2026-08-14

  The reference study identifies a hormone–chromatin–chemokine pathway in which trophoblast-derived hCG increases EZH2-associated H3K27me3 at the CXCL10 promoter in human decidual stromal cells. This mechanism links placental signaling to reduced CD8 T-cell recruitment and provides a useful framework for studying epigenetic control of immune adaptation at the maternal–fetal interface.

• T7 RNA Polymerase for Precise In Vitro RNA Synthesis

  2026-08-14

  T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes DNA templates carrying a T7 promoter. Its defined promoter recognition supports in vitro RNA synthesis for research workflows, including RNA vaccine production, antisense RNA, and RNAi studies.

• Bestatin (Ubenimex): Mechanism & Research Guide

  2026-08-13

  Bestatin, also called Ubenimex, is a research aminopeptidase inhibitor with reported activity against cytosol aminopeptidase, aminopeptidase N, zinc aminopeptidase, and aminopeptidase B. Its effects are assay-dependent: a peer-reviewed fibrin-matrix model found enhanced endothelial tube formation, so Bestatin should not be labeled universally anti-angiogenic.

8509 records 1/568 page Next 12345 下5页 Last page